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Introduction
Ulinastatin, an urinary protease inhibitor, might reduce
mortality of patients with systemic inflammatory
response syndrome such as ARDS [1] and sepsis [2].
Objectives
Our aim was to evaluate the effectiveness of ulinastatin
on 28-day mortality among patients with multiple organ
failure.
Methods
We conducted a retrospective observational study of
patients who were diagnosed multiple organ failure
within 24 hours from admission in a general ICU of a
tertiary care hospital in Japan. The study duration was
from January 2009 to December 2012. The primary out-
come was 28-day all cause mortality. The intervention
was received ulinastatin for three days and more.
Patients were also stratified by category of diseases as
subgroup analysis.
Results
A total of 212 patients with multiple organ failure met inclu-
sion criteria during this study period. At baseline, mean age
was 66.2 ± 14.7 years old, male was 146/212 (69%), mean
APACHE II score was 24.7 ± 7.9, 206/212 (97 %) patients
received mechanical ventilation, and 205/212 (96 %) patients
were on vasopressor. Overall, 79/212 (37%) patients received
ulinastatin. 28-day all cause mortality was 43/212 (20%).
There were no significant differences between ulinasatin
group and control group in age, gender, APACHE II
score. Ulinastatin group had higher prevalence of sepsis
(35/79 (44.3%) vs. 29/133 (21.8%), P = 0.001). They were
more likely to receive corticosteroid, vasopressor, renal repla-
cement therapy, and veno-arterial extra-corporeal membra-
nous oxygenation (VA-ECMO). The mortality was not
significantly different between the ulinastatin group and con-
trol group (20/79 (25.3%) vs. 23/133 (17.3%), P = 0.163).
In logistic regression after adjusting for APACHE II score,
there was not significant difference in the mortality (OR =
1.59; 95% CI, 0.79 - 3.21). The result was similar after adjust-
ing for APACHE II score, sepsis, respiratory disorder, thera-
peutic interventions including corticosteroid, vasopressor,
renal replacement therapy, and VA-ECMO. (OR = 1.29; 95%
CI, 0.56 - 2.99). In sepsis patients, ulinastatin did not reduce
the mortality, either. (OR = 1.92; 95% CI, 0.52 - 7.13).
Conclusions
Ulinastatin was not associated with survival in patients
with multiple organ failure.
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